---
title: Real-world experience of patients with multiple myeloma receiving ide-cel after
  a prior BCMA-targeted therapy
date: '2023-08-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37558706/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230810180906&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Most patients with multiple myeloma experience disease relapse after
  treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data
  describing outcomes for patients treated with sequential BCMA-TT are limited. We
  analyzed clinical outcomes for patients infused with standard-of-care idecabtagene
  vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US
  medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug
  conjugate, ...
disable_comments: true
---
Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, ...